{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:30:48Z","timestamp":1792467048803,"version":"4.5.0"},"reference-count":58,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n The mifepristone-misoprostol medication abortion regimen became available in Canada as a normally prescribed medication, without restrictions, in 2017. Despite rapid uptake, patients have reported difficulty accessing this time-sensitive medication.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To quantify mifepristone availability within 3 calendar days at community pharmacies.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This population-based, cross-sectional study using a mystery caller survey was conducted from July to August 2024 at community pharmacies in British Columbia (BC), Canada.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Surveyor posing as a patient with a prescription for mifepristone who requests to pick up the medication within 3 calendar days. For nondispensing pharmacies (ie, unable to dispense within 3 days), surveyors requested a referral to a dispensing pharmacy.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Proportion of pharmacies that could dispense mifepristone or provide a valid referral to a dispensing pharmacy; proportion of reproductive-aged (15-49 years) female population residing within 15-minute walking and 15-, 30-, and 60-minute driving times of a dispensing pharmacy, and proportion of the population with poor local availability (&amp;lt;50% of available pharmacies dispense mifepristone).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 1460 of 1482 community pharmacies, 962 (66%) could dispense mifepristone within 3 days and 169 (12%) provided a valid referral. Only one-third of nondispensing pharmacies (169 of 498 pharmacies [34%]) provided a valid referral to a dispensing pharmacy; 329 pharmacies (23%) neither dispensed within 3 days nor provided a valid referral. Almost all reproductive-aged females (1\u202f095\u202f915 of 1\u202f110\u202f218 females [99%]) in BC lived within a 15-minute drive of a mifepristone-dispensing pharmacy. Urban pharmacies were more likely to be nondispensing and nonreferring (relative risk [RR], 1.78; 95% CI, 1.19-2.80) and less likely to offer same-day dispensing (RR, 0.39; 95% CI, 0.30-0.51) compared with rural pharmacies. Populations in areas with the most residential instability (RR, 1.41; 95% CI, 1.19-1.67) or greater ethnocultural diversity (RR, 1.36; 95% CI, 1.15-1.61) had poorer local availability of mifepristone-dispensing pharmacies.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This cross-sectional study found 99% of reproductive-aged BC females lived within a 15-minute drive of a mifepristone-dispensing pharmacy; however, despite relatively good geographic coverage and mifepristone being available as a routine prescription, 23% of pharmacies neither dispensed within 3 days nor provided a valid referral, putting the onus on patients to identify a dispensing pharmacy. These findings may inform policy and initiatives to enhance pharmacist referral networks and improve mifepristone access, as well as service planning for international jurisdictions considering a similar medication abortion framework.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.42096","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:31:07Z","timestamp":1762446667000},"page":"e2542096","source":"Crossref","is-referenced-by-count":1,"title":["Mifepristone Access Through Community Pharmacies When Regulated as a Routine Prescription Medication"],"prefix":"10.1001","volume":"8","author":[{"given":"Elizabeth","family":"Nethery","sequence":"first","affiliation":[{"name":"Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Xu","sequence":"additional","affiliation":[{"name":"Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carissa S. Y.","family":"Chan","sequence":"additional","affiliation":[{"name":"Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Helmer-Smith","sequence":"additional","affiliation":[{"name":"Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Centre for Health Services and Policy Research, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Stucchi","sequence":"additional","affiliation":[{"name":"Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Centre for Health Services and Policy Research, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Mooney","sequence":"additional","affiliation":[{"name":"Centre for Health Services and Policy Research, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enav Z.","family":"Zusman","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Department of Obstetrics & Gynaecology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Dunn","sequence":"additional","affiliation":[{"name":"Department of Family & Community Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pammett","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Northern Health Authority, Prince George, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy V.","family":"Norman","sequence":"additional","affiliation":[{"name":"Department of Family Practice, Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Department of Public Health, Environments and Society, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Guarna","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynaecology, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Law","sequence":"additional","affiliation":[{"name":"Centre for Health Services and Policy Research, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada"},{"name":"Centre for Health Policy, O\u2019Brien Institute for Public Health, University of Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Schummers","sequence":"additional","affiliation":[{"name":"Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"zoi251145r1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s13669-020-00294-w","article-title":"Global abortion policies database: a descriptive analysis of financial coverage for abortion care.","volume":"9","author":"Lavelanet","year":"2020","journal-title":"Curr Obstet Gynecol Rep"},{"issue":"7","key":"zoi251145r2","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jogc.2016.04.005","article-title":"Medications used in evidence-based regimens for medical abortion: an overview.","volume":"38","author":"Soon","year":"2016","journal-title":"J Obstet Gynaecol Can"},{"issue":"4","key":"zoi251145r3","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jogc.2016.01.002","article-title":"Medical abortion.","volume":"38","author":"Costescu","year":"2016","journal-title":"J Obstet Gynaecol Can"},{"issue":"4","key":"zoi251145r4","first-page":"e209","article-title":"Abortion health services in Canada: results of a 2012 national survey.","volume":"62","author":"Norman","year":"2016","journal-title":"Can Fam Physician"},{"issue":"1","key":"zoi251145r6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.contraception.2012.06.011","article-title":"First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review.","volume":"87","author":"Raymond","year":"2013","journal-title":"Contraception"},{"issue":"5","key":"zoi251145r7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1370\/afm.2562","article-title":"Perspectives among Canadian physicians on factors influencing implementation of mifepristone medical abortion: a national qualitative study.","volume":"18","author":"Munro","year":"2020","journal-title":"Ann Fam Med"},{"issue":"1","key":"zoi251145r8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1056\/NEJMsa2109779","article-title":"Abortion safety and use with normally prescribed mifepristone in Canada.","volume":"386","author":"Schummers","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi251145r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.4516","article-title":"Trends in Abortion Rates in Ontario, Canada.","volume":"8","author":"Schummers","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi251145r12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/AOG.0000000000000945","article-title":"Abortion-related mortality in the United States: 1998-2010.","volume":"126","author":"Zane","year":"2015","journal-title":"Obstet Gynecol"},{"key":"zoi251145r13","first-page":"3602","article-title":"Is medical abortion feasible in primary care? Regulating mifepristone as a normal prescription: effect on abortion workforce.","volume":"21","author":"Norman","year":"2023","journal-title":"Ann Fam Med"},{"issue":"5","key":"zoi251145r14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jogc.2022.02.088","article-title":"Mifepristone\u2019s effect on the abortion workforce and rural services in Ontario.","volume":"44","author":"Norman","year":"2022","journal-title":"J Obstet Gynaecol Can"},{"issue":"11","key":"zoi251145r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogc.2023.06.009","article-title":"Approved but unavailable: a mystery-caller survey of mifepristone access in a large Ontario city.","volume":"45","author":"Guarna","year":"2023","journal-title":"J Obstet Gynaecol Can"},{"issue":"4","key":"zoi251145r18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1177\/17151635231176270","article-title":"Dispensing mifepristone for medical abortion in Canada: pharmacists\u2019 experiences of the first year.","volume":"156","author":"Zusman","year":"2023","journal-title":"Can Pharm J (Ott)"},{"issue":"10","key":"zoi251145r19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-063370","article-title":"Pharmacist direct dispensing of mifepristone for medication abortion in Canada: a survey of community pharmacists.","volume":"12","author":"Zusman","year":"2022","journal-title":"BMJ Open"},{"issue":"0","key":"zoi251145r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2025.110945","article-title":"Not here, not now: a mystery caller study of availability of mifepristone in community pharmacies in Alberta, Canada.","volume":"149","author":"Brennand","year":"2025","journal-title":"Contraception"},{"issue":"13","key":"zoi251145r22","doi-asserted-by":"publisher","first-page":"E345","DOI":"10.1503\/cmaj.241505","article-title":"Changes in local access to mifepristone dispensed by community pharmacies for medication abortion in Ontario: a population-based repeated cross-sectional study.","volume":"197","author":"Schummers","year":"2025","journal-title":"CMAJ"},{"key":"zoi251145r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2024.110745","article-title":"Exploring the availability and accessibility of medication abortion pills in Delhi, India: a mystery client study in community pharmacies.","volume":"143","author":"Dixit","year":"2025","journal-title":"Contraception"},{"issue":"6","key":"zoi251145r24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2471\/BLT.20.250878","article-title":"Ethical considerations for mystery shopper studies of pharmaceutical sales.","volume":"98","author":"Collins","year":"2020","journal-title":"Bull World Health Organ"},{"issue":"1","key":"zoi251145r25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/0020852315618018","article-title":"The mystery shopper: a tool to measure public service delivery?","volume":"84","author":"Jacob","year":"2018","journal-title":"Int Rev Adm Sci"},{"issue":"1","key":"zoi251145r26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13690-022-00979-z","article-title":"Secret shopper studies: an unorthodox design that measures inequities in healthcare access.","volume":"80","author":"Rankin","year":"2022","journal-title":"Arch Public Health"},{"issue":"23","key":"zoi251145r28","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMoa1715726","article-title":"Mifepristone pretreatment for the medical management of early pregnancy loss.","volume":"378","author":"Schreiber","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi251145r35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.12927\/hcpol.2011.22097","article-title":"Geographic accessibility of community pharmacies in ontario.","volume":"6","author":"Law","year":"2011","journal-title":"Healthc Policy"},{"key":"zoi251145r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jth.2024.101819","article-title":"Impact of distance and\/or travel time on healthcare service access in rural and remote areas: a scoping review.","volume":"37","author":"Mseke","year":"2024","journal-title":"J Transp Health"},{"issue":"2","key":"zoi251145r38","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/bmjsrh-2024-202379","article-title":"Nurse practitioner medication abortion providers in Canada: results from a national survey.","volume":"51","author":"Stirling-Cameron","year":"2025","journal-title":"BMJ Sex Reprod Health"},{"issue":"1","key":"zoi251145r39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ijpp.12567","article-title":"Does rural and urban community pharmacy practice differ? A narrative systematic review.","volume":"28","author":"Howarth","year":"2020","journal-title":"Int J Pharm Pract"},{"issue":"1","key":"zoi251145r40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/ijpp\/riae061","article-title":"Rural pharmacist and consumer perspectives of expanded pharmacy services to address inequity in accessing health services.","volume":"33","author":"Taylor","year":"2025","journal-title":"Int J Pharm Pract"},{"issue":"5","key":"zoi251145r42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215837","article-title":"The impacts of medication shortages on patient outcomes: a scoping review.","volume":"14","author":"Phuong","year":"2019","journal-title":"PLoS One"},{"issue":"8","key":"zoi251145r43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/15265161.2022.2075976","article-title":"The ethics of access: reframing the need for abortion care as a health disparity.","volume":"22","author":"Watson","year":"2022","journal-title":"Am J Bioeth"},{"key":"zoi251145r44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.contraception.2022.03.020","article-title":"Provision of first-trimester medication abortion in 2019: Results from the Canadian abortion provider survey.","volume":"113","author":"Ennis","year":"2022","journal-title":"Contraception"},{"issue":"3","key":"zoi251145r45","doi-asserted-by":"publisher","first-page":"E856","DOI":"10.9778\/cmajo.20210232","article-title":"Abortion services and providers in Canada in 2019: results of a national survey.","volume":"10","author":"Renner","year":"2022","journal-title":"CMAJ Open"},{"issue":"4","key":"zoi251145r46","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/AOG.0000000000002212","article-title":"Safety of medical abortion provided through telemedicine compared with in person.","volume":"130","author":"Grossman","year":"2017","journal-title":"Obstet Gynecol"},{"key":"zoi251145r47","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2022.100200","article-title":"Safety and effectiveness of self-managed medication abortion provided using online telemedicine in the United States: a population based study.","author":"Aiken","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"1","key":"zoi251145r48","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13012-021-01144-w","article-title":"Pharmacist dispensing of the abortion pill in Canada: diffusion of innovation meets integrated knowledge translation.","volume":"16","author":"Munro","year":"2021","journal-title":"Implement Sci"},{"issue":"1","key":"zoi251145r49","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1186\/s12913-023-09543-z","article-title":"A qualitative analysis of pharmacists\u2019 attitudes towards provision of medication abortion.","volume":"23","author":"Sandoval","year":"2023","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"zoi251145r50","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.whi.2022.06.007","article-title":"\u201cNo big deal\u201d: a qualitative study of pharmacists\u2019 perspectives on dispensing mifepristone for medication abortion.","volume":"32","author":"Kaller","year":"2022","journal-title":"Womens Health Issues"},{"issue":"4","key":"zoi251145r51","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/AOG.0000000000004312","article-title":"Medication abortion with pharmacist dispensing of mifepristone.","volume":"137","author":"Grossman","year":"2021","journal-title":"Obstet Gynecol"},{"issue":"3","key":"zoi251145r53","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1177\/17151635211005503","article-title":"Pharmacist checklist and resource guide for mifepristone medical abortion: user-centred development and testing.","volume":"154","author":"Rebic","year":"2021","journal-title":"Can Pharm J (Ott)"},{"issue":"1","key":"zoi251145r56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/jme.2025.46","article-title":"Origin of \u201cconscientious objection\u201d in health care: how care denials became enshrined into law because of abortion.","volume":"53","author":"Fiala","year":"2025","journal-title":"J Law Med Ethics"},{"issue":"3","key":"zoi251145r57","doi-asserted-by":"publisher","first-page":"e246","DOI":"10.1016\/S2468-2667(25)00010-6","article-title":"Abortion care in Alberta, Canada, from 2012 to 2023: a population-based, cross-sectional analysis of use and geographical access.","volume":"10","author":"Brennand","year":"2025","journal-title":"Lancet Public Health"},{"key":"zoi251145r5","unstructured":"Health Canada. MIFEGYMISO (mifepristone and misoprostol tablets): Canadian Distribution and Administration Program. Government of Canada. Published May 18, 2017. Accessed December 4, 2024. https:\/\/recalls-rappels.canada.ca\/en\/alert-recall\/mifegymiso-mifepristone-and-misoprostol-tablets-canadian-distribution-and"},{"key":"zoi251145r9","unstructured":"Canadian Institute for Health Information. Induced abortions in Canada. Updated March 20, 2025. Accessed October 7, 2025. https:\/\/www.cihi.ca\/en\/induced-abortions-in-canada"},{"key":"zoi251145r11","unstructured":"World Health Organization. Abortion care guideline. World Published March 8, 2022. Accessed October 7, 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240039483"},{"key":"zoi251145r16","unstructured":"Alberta dispenses fewer prescriptions for abortion pills than neighbouring provinces, data shows. The Globe and Mail. Published March 1, 2022. Accessed March 11, 2025. https:\/\/www.theglobeandmail.com\/canada\/alberta\/article-alberta-dispenses-fewer-prescriptions-for-abortion-pills-than\/"},{"key":"zoi251145r17","unstructured":"Weeks? C. Abortion-pill obstacles: How doctors\u2019 reluctance and long-distance travel stop many Canadians from getting Mifegymiso. The Globe and Mail. Published July 13, 2019. Accessed March 11, 2025. https:\/\/www.theglobeandmail.com\/canada\/article-abortion-pill-obstacles-how-doctors-reluctance-and-long-distance\/"},{"key":"zoi251145r21","unstructured":"Government of British Columbia. PharmaCare Policy Manual (Unified). Province of British Columbia. Updated September 16, 2025. Accessed October 7, 2025. https:\/\/www2.gov.bc.ca\/gov\/content\/health\/practitioner-professional-resources\/pharmacare\/pharmacare-publications\/pharmacare-policy-manual-unified"},{"key":"zoi251145r27","unstructured":"College of Pharmacists of British Columbia. Licensed Community Pharmacies Directory. Accessed October 7, 2025. https:\/\/www.bcpharmacists.org\/list-community-pharmacies"},{"key":"zoi251145r29","unstructured":"Government of Canada IAP on RE. Tri-council policy statement: ethical conduct for research involving humans: TCPS 2. Published 2022. Accessed December 4, 2024. https:\/\/ethics.gc.ca\/eng\/policy-politique_tcps2-eptc2_2022.html"},{"key":"zoi251145r30","unstructured":"Geoapify Geocoding API and OpenStreetMap. Accessed October 7, 2025. https:\/\/www.geoapify.com\/openstreetmap-geocoding\/"},{"key":"zoi251145r31","unstructured":"Government of British Columbia. Community Health Service Area Boundaries. Published April 1, 2019. Accessed December 2, 2024. https:\/\/open.canada.ca\/data\/en\/dataset\/68f2f577-28a7-46b4-bca9-7e9770f2f357"},{"key":"zoi251145r32","unstructured":"Statistics Canada. 2021 Census Boundary files. Government of Canada. Updated September 29, 2023. Accessed December 2, 2024. https:\/\/www12.statcan.gc.ca\/census-recensement\/2021\/geo\/sip-pis\/boundary-limites\/index2021-eng.cfm?year=21"},{"key":"zoi251145r33","unstructured":"Statistics Canada. Canadian Index of Multiple Deprivation: Dataset, 2021. Published November 10, 2023. Accessed October 7, 2025. https:\/\/www150.statcan.gc.ca\/n1\/en\/catalogue\/452000012023001"},{"key":"zoi251145r34","unstructured":"ESRI Inc. ArcGIS Pro (Service Area Analysis). Accessed October 7, 2025. https:\/\/www.esri.com\/en-us\/arcgis\/products\/arcgis-pro\/overview"},{"key":"zoi251145r37","unstructured":"R Core Team. The R Project for statistical computing. Accessed October 7, 2025. https:\/\/www.r-project.org"},{"key":"zoi251145r41","unstructured":"College of Pharmacists of British Columbia. Mifegymiso. Updated November 7, 2017. Accessed April 10, 2025. https:\/\/www.bcpharmacists.org\/mifegymiso"},{"key":"zoi251145r52","unstructured":"The Society of Obstetricians and Gynaecologists of Canada. Medication Abortion in Canada. Accessed April 10, 2025. https:\/\/caps.sogc.org\/"},{"key":"zoi251145r54","unstructured":"Center for Drug Evaluation and Research. Questions and answers on mifepristone for medical termination of pregnancy through ten weeks gestation. US FDA. Updated February 11, 2025. Accessed August 22, 2025. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/questions-and-answers-mifepristone-medical-termination-pregnancy-through-ten-weeks-gestation"},{"key":"zoi251145r55","unstructured":"Australian Government, Therapeutic Goods Administration (TGA). Amendments to restrictions for prescribing of MS-2 Step (mifepristone and misoprostol). Published July 11, 2023. Accessed August 22, 2025. https:\/\/www.tga.gov.au\/news\/media-releases\/amendments-restrictions-prescribing-ms-2-step-mifepristone-and-misoprostol"},{"key":"zoi251145r58","unstructured":"Canadian Pharmacists Association. Practice development resources: sexual and reproductive health. Accessed August 13, 2025. https:\/\/www.pharmacists.ca\/advocacy\/practice-development-resources\/sexual-and-reproductive-health\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2841040\/nethery_2025_oi_251145_1761850423.28278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:31:10Z","timestamp":1762446670000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2841040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.42096","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]}}}